itd-1

ITD1 是一个选择性的TGFβ受体抑制剂(IC50:460 nM)。

(+)-ITD-1 是一种TGF-β抑制剂，特别抑制TGF-β2，其IC50值为0.46 μM。它不仅促进TGF-βII型受体（TGFBR2）的降解，还促进心肌细胞的分化。此外，(+)-ITD-1 在小鼠胚胎干细胞（mESCs）的早期分化过程中，有效抑制中胚层的形成。

HM43239 是一种具有口服活性和选择性 FLT3抑制剂，IC50值为 1.1 nM (FLT3 野生型)、1.8 nM (FLT3 ITD 突变型) 和 1.0 nM (FLT3 D835Y 突变型)。HM43239 作为可逆的 I 型抑制剂直接抑制 FLT3 的激酶活性，并调节 p-STAT5, p-ERK SYK, JAK1 2 和 TAK1。HM43239 抑制白血病细胞的增殖并诱导其凋亡 (apoptosis)。

GTP-14564是一种新型酪氨酸激酶抑制剂，对 wt-FLT3和ITD-FLT3也具有抑制作用。GTP-14564 在 3μ m 处抑制表达 ITD-FLT3 的白细胞介素-3 非依赖性 Ba F1 的生长，而需要高 30 倍的 GTP-14564 浓度来抑制表达野生型 FLT3 的 Ba F3 的 FLT3 配体依赖性生长 （wt-FLT3）。

CDDD11-8 is an orally administered, highly potent and selective CDK9 and FLT3-ITD inhibitor, with K i values of 8 nM and 13 nM, respectively. It effectively reduces the proliferation of leukemia cell lines, showing particular efficacy against those with the FLT3-ITD mutation [1] [2].

PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD) with an IC50 of 0.6 nM and exhibits anti-proliferative activity.

Desmorpholinyl Quizartinib-PEG2-COOH is a compound featuring an FLT-3 ligand and a PEG-based PROTAC linker. It is employed in the synthesis of PROTAC FLT-3 degrader 1, which serves as a degrader for the FLT-3 internal tandem duplication (ITD) through PROTAC technology. The degrader exhibits an IC50 of 0.6 nM.

FI-700 is a novel and potent FLT3 inhibitor with promising antileukemia activity. FI-700 showed a potent IC(50) value against FLT3 kinase at 20 nmol L in an in vitro kinase assay. FI-700 showed selective growth inhibition against mutant FLT3-expressing leukemia cell lines and primary acute myeloid leukemia cells, whereas it did not affect the FLT3 ligand (FL)-driven growth of Wt-FLT3-expressing cells. Oral administration of FI-700 induced the regression of tumors in a s.c. tumor xenograft model and increased the survival of mice in an i.v. transplanted model. Furthermore, FI-700 treatment eradicated FLT3 ITD-expressing leukemia cells, both in the peripheral blood and in the bone marrow. (Source: Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4575-82.)

PF15 TFA是一种连接FLT3 kinase配体和CRBN配体的PROTAC，作为FLT3-ITD的高选择性降解剂，DC50值为76.7 nM。该化合物可显著抑制FLT3-ITD阳性细胞增殖，并降低FLT3和STAT5磷酸化水平。PF15 TFA亦能抑制小鼠模型的肿瘤生长，并可用于白血病研究。

FLT3-IN-23作为JFMS样脂氨酸激酶3(FLT3)的抑制剂，表现出7.42 nM的IC50值。该化合物针对带有多种FLT3-TKD与FLT3-ITD-TKD突变的BaF3细胞显示出显著的抗增殖效果。

HP1142 is a highly effective and specific inhibitor targeting the FLT3 receptor tyrosine kinase, with a particular affinity for its mutant variant FLT3 ITD. It exhibits a benzoimidazole scaffold-based structure, making it a promising compound for investigating and studying the FLT3 ITD mutation in the context of leukemia research [1].

HDAC10-IN-2 (化合物 10c) 调节侵袭性 FLT3-ITD 阳性急性髓系白血病细胞的自噬。HDAC10-IN-2是HDAC10的高选择性抑制剂 (IC50 = 20 nM)。

FLT3 ITD-IN-1 (Compound 1) is a highly potent inhibitor of FLT3 internal tandem duplications (FLT3-ITD). It exhibits remarkable inhibitory effects against FLT3 and FLT3-ITD, with impressive IC50 values of 38.2 nM and 144.1 nM, respectively. Moreover, FLT3 ITD-IN-1 shows exceptional antiproliferative activities against several acute myeloid leukemia cell lines [1].

HDAC10-IN-1 (化合物 13b) 是一种有效且高选择性的HDAC10抑制剂 (IC 50 = 58 nM)，可用于调节侵袭性 FLT3-ITD 阳性急性髓系白血病细胞的自噬。

Sorafenib N-oxide is an active metabolite of sorafenib , an inhibitor of Raf-1, B-RAF, and receptor tyrosine kinases. Sorafenib N-oxide inhibits FLT3 that contains the internal tandem duplication mutation (FLT3-ITD; Kd = 70 nM) and inhibits proliferation of MV4-11 acute myeloid leukemia (AML) cells expressing FLT3-ITD (IC50 = 25.8 nM). It is selective for AML cell lines containing FLT3-ITD over lines containing wild-type FLT3 (IC50s = 3.9-13.3 μM). Sorafenib N-oxide is also a linear-mixed inhibitor of the cytochrome P450 (CYP) isoform CYP3A4 (Ki = 15 μM in human liver microsomes).

FLT3 TrKA-IN-1 是一种有效的 FLT3 TrKA 双激酶抑制剂，能够作用于 FLT3 (IC50: 43.8 nM)、FLT3-ITD (IC50: 97.2 nM)、FLT3-TKD (IC50: 92.5 nM) 和 TrKA (IC50: 23.6 nM)。FLT3 TrKA-IN-1 能够将细胞周期阻滞在 G0 G1 期，并诱导细胞凋亡 (apoptosis)，具有抗增殖作用。FLT3 TrKA-IN-1 具有潜力进行急性髓性白血病 (AML) 的研究。

AC-4-130, a powerful inhibitor of the SH2 domain of STAT5, effectively hinders STAT5 activation, dimerization, nuclear translocation, and transcription of genes reliant on STAT5. This compound directly binds to STAT5, ultimately leading to cell cycle arrest and apoptosis in FLT3-ITD-driven leukemic cells. AC-4-130 exhibits notable anti-cancer properties and effectively suppresses abnormal STAT5 activity in acute myeloid leukemia (AML), making it a promising therapeutic option [1].

PROTACFLT3 CDK9 degrader-1 是一种有效的FLT3和CDK9双PROTAC 降解剂。PROTACFLT3 CDK9 degrader-1 诱导细胞凋亡 (Apoptosis) 并有效降解靶蛋白FLT3和 CDK9。PROTACFLT3 CDK9 degrader-1具有研究 FLT3-ITD 突变型 AML 的潜力。

HP1328 is a highly effective inhibitor of FLT3 receptor tyrosine kinase with a specific focus on FLT3 ITD mutation. It belongs to the benzoimidazole scaffold-based compound family. Significantly reducing the leukemia burden, HP1328 effectively extends the survival of mice afflicted with FLT3 ITD leukemia [1].

Antiproliferative agent-30 (Compound 8g) 抑制微管蛋白组装且可抑制FLT3及Abl1。该化合物展现出对血管的破坏活性，并对多种癌细胞系表现出强效的抗增殖能力，包括HCT-116、K562及MV-4-11细胞（IC50值分别为0.054 nM、0.008 nM、0.144 nM）。此外，Antiproliferative agent-30 亦对携带FLT3-ITD-TKD突变的AML显示出抗癌效果。

LT-540-717（化合物32）作为一款有效的FLT3抑制剂（IC50=0.62 nM），展现出抗增殖活性。此外，LT-540-717 抑制多个获得性FLT3突变型，包括FLT3 (ITD, D835V)、FLT3 (ITD, F691L)、FLT3 (D835Y) 及FLT3(D835V)，显示其作为抗AML剂的潜力。

Tuspetinib (HM43239) hydrate 是具备口服活性的选择性 FLT3 抑制剂，IC50 值分别为 1.1 nM（FLT3 野生型）、1.8 nM（FLT3 ITD 突变型）和 1.0 nM（FLT3 D835Y 突变型）。Tuspetinib hydrate 作为可逆的 I 型抑制剂直接抑制 FLT3 激酶活性，调节 p-STAT5, p-ERKSYK, JAK1 2 和 TAK1，抑制白血病细胞增殖并诱导细胞凋亡 (apoptosis)。

FLT3-IN-21（复合物LC-3）是一种高效的FLT3抑制剂，具有促进细胞凋亡的能力，其对FLT3酶的半抑制浓度（IC50）为8.4 nM。该化合物能够使细胞周期在G1期停滞，并对FLT3-ITD阳性的AML细胞系MV-4-11显示出显著的抑制作用（IC50：5.3 nM）。在小鼠体内，FLT3-IN-21以每日10 mg kg的剂量可以有效抑制MV-4-11细胞异种移植瘤的生长，肿瘤生长抑制率（TGI）达到92.16%。

Pomalidomide-C5-Dovitinib（compound 2）是链接Pomalidomide与Dovitinib的PROTAC，且与CRBN结合。该化合物在FLT3-ITD+ AML细胞中表现出增强的抗增殖能力，通过泛素-蛋白酶体依赖性途径促进FLT3-ITD和KIT蛋白的降解，并彻底抑制其下游信号传导，显示出研究FLT3-ITD+急性髓系白血病的潜力。